Tips For Successfully Scaling Your cGMP Manufacturing

Advanced therapies, such as viral vectors, cell therapies, plasmids, mAbs, are the future of how we will treat cancer, immune, neurologic and genetic conditions, and devastating rare diseases. Yet delivering them at scale is challenging. What are the specific obstacles to expanding manufacturing capacity? What does one need to consider for a successful “CapEx” project?

Several cell therapy industry leaders participated in a panel discussion to share their thoughts and first-hand experiences. Based on the conversation, it's clear that scalable, flexible, proven solutions will solve most issues, from time constraints and bandwidth issues to scientific expertise and staffing shortages. Learn what to look for in a solutions provider and what these leaders recommend for navigating your road ahead.

Speakers
Erwin Cammaart,
Executive Director, Process Development, Iovance Biotherapeutics, Inc.

Matthew M. Hewitt
Executive Director, Scientific Services Cell and Gene Therapy, Charles River Laboratories

Carol Houts
VP of Quality & Business Strategy, Germfree

Michael Paglia
COO, ElevateBio, BaseCamp

Raymond D. Stapleton, Ph.D.
Executive Vice President, Pharmaceutical Sciences and Manufacturing, Genocea

Moderator: Shannon Eaker, Cell and Gene Therapy Enterprise Technical Leader, Cytiva